natgillin/translations-raw huggingface dataset:
separating said precipitated sulphate compounds from said first leach solution; and 
razdvajanje (245) spomenutih istaloženih sulfatnih spojeva iz spomenute prve otopine za ispiranje; i
In a preferred embodiment, the adeno-associated vector is used to produce adeno-associated particles where the serotype is 1, 2, 5, 7, 8 or 9. 
Genski konstrukt u skladu s patentnim zahtjevom 4, naznačen time što je serotip adenoasociranog vektora 1, 2, 5, 7,81ili9.
A group B adenovirus comprising a sequence of formula (I): 
Replikacijski kompetentni onkolitički adenovirus iz skupine B, naznačen time što sadrži slijed formule (I):
A salt according to claim 1, wherein in the amino nicotinic acid derivative of formula (I): 
Sol prema zahtjevu 1, naznačena time, što u derivatu aminonikotinske kiseline formule (I):
With this system, the powder particles are fluidized in a conical shaped bed by the inlet of hot air, which mixes the ingredients of the sugar replacer formulation. 
Tim se postupkom praškaste čestice fluidiziraju u koničnom spremniku u struji vrućeg zraka koji miješa sastojke sastavine koja zamjenjuje šećer.
frequency transform means for transforming the low frequency component obtained by the core decoding means into a frequency domain; high frequency generating means for generating a high frequency component by copying the low frequency component transformed into the frequency domain by the frequency transform means from a low frequency band to a high frequency band; 
pretvarač frekvencije za pretvorbu niskofrekventne komponente dobivene iz osnovnog dekodera u frekventno područje; visokofrekventni generator za generiranje visokofrekventne komponente kopiranjem niskofrekventne komponente koju pretvarač frekvencije pretvara u frekventno područje iz niskofrekventnog pojasa u visokofrekventni pojas;
Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use. 
Otopine za paranteralnu uporabu mogu također biti priređeni kao suhi preparati koji se trebaju otopiti s pogodnim otapalom bez pripreme neposredno prije uporabe.
In other specific aspects R5 is hydrogen, C1-3alkyl, or —CH2-pyridyl; or R5 is hydrogen or C1-3alkyl. 
zajedno tvore C;valkilenil; i R" je vodik, C,alkil ili piridil; ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
Therefore, the fluid 12 is preferably transported and atomised purely mechanically, particularly without a propellant gas and without electricity. 
Zbog toga se fluid 12 ponajprije transportira i atomizira čisto mehanički, posebno bez potisnog plina i bez elektriciteta.
The method of claim 1, wherein the cumulative total amount of glutamate per unit volume in said medium is less than 1 mM. 
Postupak prema Zahtjevu 1, naznačen time, što je kumulativna ukupna količina glutamata po jedinici volumena u spomenutom mediju manja od približno 1 mM,
The pharmaceutical composition according to claim 1, comprising at least two peptides, wherein said peptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10, or SEQ ID NO: 12 to SEQ ID NO: 23; provided that the composition comprises at least one peptide comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 12 or SEQ ID NO: 13 or a variant or salt thereof; and further comprising mannitol and poloxamer 188, wherein the ratio by weight of peptides to mannitol to poloxamer 188 ranges is in the range including and between 1:5:1.5 to 1:8:2.2. 
Farmaceutski sastav prema zahtjevu 1, koji se sastoji od najmanje dva peptida, gdje spomenuti peptidi sadrže slijed aminokiselina odabranih iz skupina koje se sastoje od ID br. baz.: 1 do ID br. baz.: 10, ili ID br. baz.: 12 do ID br. baz.: 23; pod uvjetom da sastav sadrži najmanje jedan peptid koji uključuje ID br. baz.:1, ID br. baz.: 2, ID br. baz.: 12 ili ID br. baz.: 13 ili njihove soli koje dalje sadrže manitol i poloksamer 188, gdje je omjer prema težini peptida prema manitolu prema poloksameru 188 u rasponu uključujući i između 1:5:15 do 1:8:2.2.
or A1 and A2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of: thiomorpholinyl, piperidinyl, pyrrolidinyl, and morpholinyl; wherein said piperidinyl, and pyrrolidinyl are optionally substituted with CF3, CH2F, CH2CH2F, C(1-2)alkyl, -CN, OH, or CH2OH, and up to three additional substituents selected from the group consisting of CH3, and F; 
o LAI domarfolii, piperidinil, pirolidinil, i morfolinil; pri čemu su navedeni piperidinil | i pirolidinil proizvoljno supstituirani s CF3, CH>F, CHoCHbF, Ca-alkil, -CN, OH, ili CH2OH, 1 do tri dodatna supstituenta odabrana iz skupine koju čine CH-, i F;
Incubate on shaker (Lab-Line model #1314, shake at setting of 4) for 60 minutes at room temperature. 
Inkubiraj u mješalici (Lab-Line model #1314, miješaj na 4) tijekom 60 minuta na sobnoj temperaturi.
The method of claim 5, wherein the mineral acid of step A7 h) is hydrochloric acid. The method of claim 2, wherein step A3 is carried out in the presence of N-bromosuccinimide. 
Postupak prema bilo kojem od zahtjeva 21 do 30, naznačen time što u navedenom koraku A7, h), navedena mineralna kiselina je klorovodična kiselina.
FIG. 7 is a side view of an exemplary embodiment of a blender container; 
Slika 7 je bočni prikaz primjera ostvarenja posude mješalice;
A process for preparing a compound of Formula XXV wherein R4 represents alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl; comprising: 
Postupak za pripremu spoja Formule XXV [image] naznačen time, da R4 predstavlja alkil, alkenil, alkinil, cikloalkil, aril, heterociklil, heteroaril, aralkil, heteroarilalkil, heterociklilalkil ili cikloalkilalkil;
The system of claim 1 wherein, for the at least one vehicle, the at least one processor dynamically determines the estimated transit time for the respective vehicle to each of at least some of the plurality of destinations to be visited during the route based at least in part on the updated respective route the vehicle is to transit. 
najmanje jedno pojačalo koje je pozicionirano tako, da očitava najmanje jedno radno stanje od barem jednog štednjaka (210), gdje je najmanje jedno pojačalo komunikacijski spojeno na radio uređaj za proizvodnju signala na udaljenom stacioniranom izvoru (102), koji pokazuje očitavanje najmanje jednog radnog stanja od barem jednog štednjaka.
The imaging material supply cartridge (24) of claim 1, wherein the access mode identified by the partition ID portion is one of a read only mode, a read/write mode, a read/write-or mode. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što je pristupni način identificiran dijelom za identificiranje particije način samo za očitavanje, način za očitavanje/upisivanje, način za očitavanje i/ili upisivanje.
Also provided is a pharmaceutical composition comprising a (heterodimeric) Ig-like molecule, or a mixture of at least two Ig-like molecules obtainable by any method according to the invention. 
Smjesa najmanje dva različita antitijela koja se može dobiti pomoću postupaka u skladu s bilo kojim od patentnih zahtjeva 1-12.
that competes with an antibody of (a). 
(a) dodatnim terapijskim sredstvom; ili
Class I caramels are prepared by heating carbohydrates with or without acids, bases or salts, but in the absence of ammonium or sulphite compounds. 
Karamele klase I se dobivaju zagrijavanjem ugljikohidrata sa ili bez kiselina, baza ili soli, ali u odsutnosti amonijevih ili sulfitnih spojeva.
Item 11. item Upwardly oriented storage according to item 9 or 10, wherein the conveyor means further comprises a guide means (241) adapted to retain a returnable item deposited in the recess as the drum is positioned in a rotary position between the second rotary position and the first output or a second output. 
Prema gore orijentirano skladište prema patentnom zahtjevu 13 ili 14, naznačeno time, što transportno sredstvo dalje sadrži sredstvo (241) za vođenje prilagođeno da zadrži povratni predmet koji se nalazi u udubljenju dok je bubanj postavljen u rotacijski položaj između drugog rotacijskog položaja i prvog izlaza ili drugog izlaza.
The pyridone derivative, or a salt thereof, according to any of (1) to (7), wherein R4 in the formula (I) represents a halogen atom, a cyano group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a hydoxymethyl group, a C1-C6 alkyl group, or a C2-C6 alkenyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 7, naznačen time da je R* u formuli (I) atom halogena, cijano grupa, C1-C6 haloalkil grupa, C1-C6 alkoksi grupa, hidrometil grupa, C1-C6 alkil grupa ili C2- C6 alkenil grupa.
The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders. 
Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-5 u proizvodnji lijeka za liječenje raka, multiple skleroze, Parkinsonove bolesti, Huntingtonove bolesti, Alzheimerove bolesti, gastrointestinalnih poremećaja i kardiovaskularnih poremećaja.
HPLC assay yield after work up was 86-92%. 
HPLC test prinosa nakon postupka je iznosio 86-92%.
This way the system manager, and/or a highly qualified person, can remotely monitor and/or guide the usually less experienced operators. 
Na taj način rukovoditelj sustava i/ili visoko pozicionirana osoba može na daljinu promatrati i/ili voditi obično manje iskusnog operatora.
These were furfurylthiol and furfurylthioacetate (see figures 1A-H). A thermally processed and stored ready to drink liquid coffee product comprising a coffee, a stabilizer, a buffer, water and a thioester flavor precursor in an amount sufficient to provide improved flavor quality to the product after thermal processing and storage of the liquid product for more than 4 months at ambient temperature and for more than 1 month at 60°C storage, wherein the thioester flavor precursor is of the general structure of R-S-CO-R', wherein R is selected from the group of methyl, ethyl, propyl, isopropyl, prenyl, furfuryl, wherein R' is selected from the group ofH, methyl, ethyl, propyl, isopropyl. 
Toplinski obrađen i uskladišten instant tekući kaveni proizvod, koji sadrži kavu, stabilizator, pufer, vođu i preteču tioesterskog okusa, u količini dovoljnoj da se postigne poboljšanje kvalitete arome proizvoda nakon toplinske obrade i skladištenja tekućeg proizvoda kroz dulje od 4 mjeseca na temperaturi okoliša, odnosno kroz dulje od 1 mjesec na 60 "C, naznačen time što preteča tioesterskog okusa ima opću strukturu R-S-CO-R", gdje se R bira iz skupine koju čine metil, etil, propil, izopropil, prenil, furfuril, a R' se bira iz skupine koju čine H, metil, etil, propil, izopropil.
The coupling according to claim 9, wherein said centering shank is hollow and comprises an internal thread which is suitable to engage a threaded pin which is rigidly associated with said stock. 
Spoj prema jednom ili više od prethodnih zahtjeva, naznačen time što je centrirajući krak (7) šupalj i obuhvaća unutarnji navoj koji je prikladan za spajanje s navojnom iglom (12) koja je čvrsto povezana s okvirom (14).
A wind turbine structure (1) according to claim 1, whereas the bearing (6) is a three-row roller bearing. 
Vjetroturbina prema zahtjevima 1-5, naznačena time što je ležište (6) dvoredno konično valjkasto ležište ili troredno valjkasto ležište.
The method of item 48, wherein the eye disorder is macular degeneration. 
Farmaceutski pripravak za uporabu prema zahtjevu 48, naznačen time da je očni poremećaj makularna degeneracija.
A pharmaceutical composition comprising a compound of formula (I) as defined in any of claims 1 to 4 and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof and physiologically acceptable carrier(s) therefore. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj formule (I) kao što je definiran u bilo kojem zahtjevu od 1 do 4 i/ili njegove geometrijske izomere i/ili stereoizomere i/ili dijastereomere i/ili njegove fiziološki prihvatljive soli i/ili njegove hidrate i/ili solvate i uz to fiziološki prihvatljive nosače.
Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin 
POSTUPAK! INTERMEDIJERNI SPOJEVI KORISNI ZA DOBIVANJE STATINA, NAROČITO
The method of item 10, wherein said CD19xCD3 bispecific single chain antibody construct comprises an amino acid sequence as set forth in SEQ ID NO. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što navedeno CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt ima aminokiselinski slijed kako što je iznijet u SEQ ID NO.
A method according to claim 1 comprising the further steps: adding one or more buffering agents; and adding a pH adjustment agent to adjust the pH to approximately 7.5-9.0. 
Postupak prema patentnom zahtjevu 41 ili 42, naznačen time što sadrži i dodatne korake: b1) dodavanje jednog ili više puferiranih sredstava; 1 b2) dodavanje sredstva za podešavanje pH vrijednosti da bi se pH podesila do približno 7.5-9.0.
The composition according to claim 11 wherein said hypertonic saline diluent includes NaCl at a concentration of from 3% to 7%. 
Pripravak sukladno zahtjevu 11 pri čemu spomenuti hipertonično slano otapalo sadrži NaCl u koncentraciji od 3% do 7%.
The method of claim 28, wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 2-5, naznačeno time što se navedeno protutijelo primjenjuje parenteralnim načinom, intravenskim načinom ili supkutanim načinom primjene.
Method according to claim 1.9 or 20, characterised in that the immunoglobulin comprises any of the loop regions of Ig-kappa or Ig-lambda comprising a modification in one of the amino acid positions within the amino acid sequence selected from the group consisting of amino acids 8 to 20, amino acids 26 to 36, amino acids 43 to 79, amino acids 83 to 85, amino acids 90 to 101, amino acids 108 to 116 and amino acids 122 to 125, wherein the numbering is according to IMGT. 
Postupak u skladu sa zahtjevom 19 ili 20, naznačen time, da imunoglobulin obuhvaća neko od područja petlje Igkapa ili Ig-lambda koja obuhvaćaju modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 26 do 36, aminokiseline 43 do 79, aminokiseline 83 do 85, aminokiseline 90 do 101, aminokiseline 108 do 116 i aminokiseline 122 do 125, pri čemu je numeriranje prema IMGT. .
A Streptococcus pneumoniae immunogenic composition comprising 9 or more, 10 or more, 11 or more, 13 or more, or 14 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197 
Imunogeni pripravak protiv bakterije Streptococcus pneumoniae, koji sadrži 10 ili više saharida kapsule iz različitih serotipova bakterije S. pneumoniae, konjugiranih s proteinskim nosačem, te što sadrži 3 ili više različitih proteinskih nosača, naznačen time što pripravak sadrži: saharid iz kapsule serotipa 19F, konjugiran s difterijskim toksoidom (DT); saharid iz kapsule serotipa 18C, konjugiran s tetanusnim toksoidom (TT); saharidi iz kapsule serotipova 1, 4, 5, 6B, 7F, 9V, 14 1 23F, konjugirani s proteinom D iz bakterije Haemophilus influenzae.
Method, according to any one of claims 4 to 7, wherein the pressure inside the elastic container is between 1 and 1.8 bars. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 5 do 10, pri čemu je otvor u palmi 1.5 do 2 m ispod krošnje.
The composition or vaccine of any one of claims 1-3 for use in a method for inducing a protective response in an animal against NDV and optionally one or more further avian pathogens, said method comprising at least one administration of the composition or vaccine. 
Pripravak ili cjepivo prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv virusa Newcastleske bolesti (NDV), virusa infektivnog bursitisa (primjerice IBDV ili virusa Gumboro-bolesti), virusa Marekove bolesti (engl.
Then the collapsed container 2 can be replaced by a new full container 2. 
Zatim se sklopljeni spremnik 2 može zamijeniti s novim punim spremnikom 2.
The compound, the pharmaceutically acceptable salt thereof, according to claim 2, wherein R1 is selected from the group consisting of 
Spoj prema patentnom zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, pri čemu je R; izabran iz grupe koja se sastoji od HA
A method according to claim 4, wherein the type of multiple sclerosis to be treated is relapsing-remitting multiple sclerosis. 
Sastav za uporabu u skladu s patentnim zahtjevom 4, pri čemu je tip multiple skleroze koju treba liječiti relapsirajuće-popuštajuća multipla skleroza.
wherein component (A) is positioned at the C-terminal end of the transporter cargo conjugate molecule, provided that component (B) is a protein or peptide sequence. 
pri čemu je komponenta (A) smještena na C-terminalnom kraju transporterske teretne konjugirane molekule, pod uvjetom da je komponenta (B) protein ili peptidna sekvenca.
The method according to claim 12, wherein the purified mixture of said cysteine-linked antibody-drug conjugates of the formula (II) has an average drug-to-antibody ratio (DAR) of from 2.6 to 2.9. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što pročišćena smjesa navedenih cisteinski vezanih konjugata protutijelo-lijek formule (ID) ima prosječni omjer lijek: protutijelo (DAR) od 2,6 do 2,9.
The cytotoxic agent according to any one of claims 14 to 17, wherein the antibody is conjugated to a cytotoxic substance via a linker. 
Citotoksično sredstvo u skladu s patentnih zahtjeva 3 do 4, naznačeno time što je protutijelo konjugirano s citotoksičnom tvari preko spojnice.
a 3,6,9-trioxa-undecane-1,11-dioxyamine linker of the formula: wherein the PSA is oxidized by incubation with a oxidizing agent to form a terminal aldehyde group at the non-reducing end of the PSA. 
3,6,9-trioksa-undekan-1,11-dioksiamin poveznica s formulom: [image] pri čemu se PSA oksidira pomoću inkubacije sa sredstvom za oksidaciju tako da nastaje terminalna aldehidna skupina na nereducirajućem kraju PSA.
cyclising a compound of formula (VI) to form a compound of formula (I): 
0) ciklizacije spoja formule (VI) da tvori spoj formule (I):
In certain embodiments, the peptides present in the composition are selected from tissue-, cancer, and/or patient-specific peptides. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6, naznačeno time da je količina prisutnih peptida u sastavu kao i u tkivu, karcinomu, te je i/ili specifična za svakog pacijenta.
This provides easy and non-cumbersome installation, set-up, and maintenance. 
To omogućuje laku i jednostavnu ugradnju, reguliranje i održavanje.
The compound, or a pharmaceutically acceptable salt or N-oxide derivative thereof as claimed in claim 2, wherein A1 and A2 are both unsubstituted methine groups. 
Tvar, ili farmaceutski prihvatljiva sol ili njen N-oksid derivat u skladu s patentnim zahtjevom 1, gdje su A1 i A2 obje nesupstituirane metinske grupe.
(0-1) providing a compound of formula IV" wherein X is Cl or Br, (0-2) substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula VI" or 
(0-1) pripravljanje spoja formule IV" gdje X je Clili Br, (0-2) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj formule VI'', ili sljedećih koraka:
The receiver of claim 5, further comprising: a time-frequency deinterleaver configured to time-frequency deinterleave constellation values corresponding to PLP data; a QAM demapper configured to demap the deinterleaved constellation values into cell words and to multiplex the demapped cell words into the PLP data; 
HR P20121038 T1 dio za demapiranje QAM-a (r713-L1) podešen za demapiranje raspletenih konstelacijskih vrijednosti u stanične Tiječi i za umnožavanje demapiranih staničnih riječi u PLP podatke; dio za raspletanje bitova (r714-L1) podešen za raspletanje bitova umnoženih PLP podataka;
a mammalian secretion signal sequence, which is optionally a human type 1 elastase signal sequence or a porcine type 1 elastase signal sequence; 
(1i) signalna sekvenca sekrecije sisara, koja je opcionalno signalna sekvenca humanog tipa 1 elastaze ili signalna sekvenca svinjske tipa 1 elastaze;
Another embodiment is a method for treating disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the Examples, wherein said disorders are selected from multiple sclerosis, atherosclerosis, Crohn's disease, and diabetes. 
Spoj prema zahtjevima 9-10 pri čemu se bolest izabire između multiple skleroze, ateroskleroze, Crohnove bolesti i dijabetesa. Farmaceutska smjesa prema zahtjevu 8 koja dalje sadrži jednu ili više drugih djelatnih tvari. HR P20110465 T1
The proline residue at position 331 in human IgG1 can also be changed to a threonine or glycine or any other polar amino acid. 
Protutijelo prema zahtjevu 1 ili 2, pri čemu je aminokiselinski prolin na položaju 331 u humanom IgG1 promijenjen u serin ili drugu polarnu aminokiselinu.
Therefore, according to a preferred aspect of the invention, this pharmaceutical composition contains dimethylfumarate at a dose range of 500 mg to 750 mg and teriflunomide at a dose range of 1 mg to 6 mg. 
(a) dimetilfumarat u rasponu doze od 500 mg do 750 mg i lakvinimod u rasponu doze od 0,05 mg do 0,25 mg; ili
The combination for use according to any one of the preceding claims, wherein desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt is administered in an add-on therapy to administration of metformin and insulin glargine. 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se dezPro**Eksendin-4(1-39)-Lyss-NH, ili/i njegova farmaceutski prihvatljiva sol primjenjuje kao pomoćna terapija uz primjenu metformina i inzulin glargina.
Uses of Cells and Organoids of the Invention 
Datum objave europskog patenta:
A method for modulating a chemical or physical property of interest of a co-crystal of any of claims 1-7, comprising: a measuring the chemical or physical property of interest for a compound having the structure and 4-hydroxybenzoic acid, 
Postupak mijenjanja kemijskog ili fizičkog svojstva od interesa sukristala u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što se sastoji u: mjerenju kemijskog ili fizičkog svojstva od interesa spoja sa strukturom [image]
A modified soluble FGF receptor Fc fusion of claim 37 wherein said cancer is selected from the group of melanoma, leukemia, renal cancer, colon cancer, ovarian cancer, prostate cancer, lung cancer, bladder cancer; breast cancer, and head and neck cancer. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 37, naznačena time što se navedeni rak bira iz skupine koju čine melanom, leukemija, rak bubrega, rak debelog crijeva, rak jajnika, rak prostate, rak pluća, rak mokraćnog mjehura, rak dojke, te rak glave i vrata.
The proNGF mutant according to claims 1 to 6, wherein the mutant is obtained by recombinant expression in prokaryotic cells, preferably in E. coli. 
proNGF mutant prema zahtjevu 1, naznačen time da se mutant dobiva pomoću rekombinantne ekspresije u prokariotskim stanicama, poželjno pomoću rekombinantne ekspresije u E. coli.